Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.86 |
| ▸ | PNP | P00491 | 8/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6901448 | 0.86 | HPRT1 (0.76) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL9054025 | 0.84 | HPRT1 (0.80) | HPRT1PNP | |
| SCHEMBL6898237 | 0.79 | FGFR1 (0.56) | HPRT1 | |
| SCHEMBL6004502 | 0.78 | HPRT1 (0.67) | HPRT1PNPBLM | |
| SCHEMBL9858092 | 0.78 | HPRT1 (0.66) | HPRT1PNPBLM | |
| SCHEMBL9054447 | 0.78 | HPRT1 (0.90) | HPRT1PNP | |
| SCHEMBL9858169 | 0.76 | HPRT1 (0.73) | HPRT1PNP | |
| SCHEMBL17194156 | 0.76 | HPRT1 (0.81) | HPRT1PNP | |
| SCHEMBL15078310 | 0.76 | HPRT1 (0.81) | HPRT1PNP | |
| SCHEMBL15078251 | 0.76 | HPRT1 (0.81) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | HPRT1 871/4885PNP 71/4885USP2 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.